Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Schoeberl

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Science Signaling|July 2, 2009
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axisBirgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, et al.
Molecular Cancer Therapeutics|November 28, 2013
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitorsJonathan B Fitzgerald, Bryan W Johnson, Jason Baum, et al.
Cancer Cell|March 16, 2010
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsQing Sheng, Xinggang Liu, Eleanor Fleming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic CancerAdam J Camblin, Emily A Pace, Sharlene Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2019
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAMJessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, et al.
NPJ Systems Biology and Applications|July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Science Signaling|July 2, 2009
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axisBirgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, et al.
Molecular Cancer Therapeutics|November 28, 2013
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitorsJonathan B Fitzgerald, Bryan W Johnson, Jason Baum, et al.
Cancer Cell|March 16, 2010
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsQing Sheng, Xinggang Liu, Eleanor Fleming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic CancerAdam J Camblin, Emily A Pace, Sharlene Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2019
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAMJessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, et al.
NPJ Systems Biology and Applications|July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
Pageof 4